Kazia CEO corrects ADS option exercise price
Kazia Therapeutics Ltd chief executive John E. Friend II reports his holdings of an American Depositary Share (ADS) option covering 30,000 ADSs.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3/A
Rhea-AI Filing Summary
Kazia Therapeutics Ltd chief executive John E. Friend II reports his holdings of an American Depositary Share (ADS) option covering 30,000 ADSs. The ADS option was granted on July 22, 2024 at an exercise price of $18.85 per ADS and expires on July 22, 2027. It vests in equal quarterly installments over three years beginning April 22, 2024, contingent on continued service. This amended Form 3 corrects the exercise price of the previously reported ADS option.
Insider Trade Summary
Holdings reported, no transactions
Holdings
Insider
Friend John E. II
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | American Depositary Share Option (Right to Buy) | -- | -- | -- |
Holdings:
American Depositary Share Option (Right to Buy) — 30,000 contracts (Direct)
Footnotes (4)
- F1. The American Depositary Shares ("ADSs") subject to the option ("ADS option") vest in equal quarterly installments over three years beginning on April 22, 2024, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on July 22, 2024.
- F2. Each ADS option is convertible into ADSs upon exercise.
- F3. Each ADS may be represented by 500 ordinary shares of the Issuer, no par per share (the "Ordinary Shares"), at any time, upon the holder's election to surrender the ADSs and withdraw the respective number of Ordinary Shares. The ADSs have no expiration date.
- F4. This Form 3/A is being filed to correct the exercise price of the ADS option granted on July 22, 2024.
Key Figures
ADS option underlying shares: 30,000 ADSs
Exercise price: $18.85 per ADS
Option expiration date: July 22, 2027
+2 more
5 metrics
ADS option underlying shares
30,000 ADSs
Underlying American Depositary Shares for CEO option holding
Exercise price
$18.85 per ADS
Corrected exercise price for ADS option granted July 22, 2024
Option expiration date
July 22, 2027
Expiration of American Depositary Share option
Vesting schedule
3 years, quarterly
Equal quarterly installments starting April 22, 2024
ADS to ordinary share ratio
1 ADS : 500 ordinary shares
Conversion relationship between ADSs and ordinary shares
Key Terms
American Depositary Shares, ADS option, exercise price, vesting, +1 more
5 terms
ADS option financial
"The American Depositary Shares ("ADSs") subject to the option ("ADS option") vest"
exercise price financial
"This Form 3/A is being filed to correct the exercise price of the ADS option"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"ADSs subject to the option vest in equal quarterly installments over three years"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Form 3/A regulatory
"This Form 3/A is being filed to correct the exercise price"
An amended Form 3 (Form 3/A) is a corrected or updated disclosure filed with regulators that revises an insider’s initial report of their ownership in a public company — typically for officers, directors or large shareholders. Investors use it like a corrected inventory list: it clarifies who owns how many shares and whether earlier reports had errors, helping assess insider confidence, possible conflicts and the accuracy of ownership records that can affect stock valuation and trust.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider position does Kazia Therapeutics (KZIA) CEO John E. Friend II report?
He reports holding an option over 30,000 American Depositary Shares. The option gives him the right to buy ADSs at a fixed exercise price, subject to vesting conditions and an expiration date in July 2027.
What is the exercise price of the Kazia Therapeutics (KZIA) CEO’s ADS option?
The ADS option has an exercise price of $18.85 per American Depositary Share. This amended filing specifically corrects that exercise price compared with the prior report, clarifying the terms governing the CEO’s option grant.
How do the Kazia Therapeutics (KZIA) CEO’s ADS options vest over time?
The ADS option vests in equal quarterly installments over three years beginning April 22, 2024. Vesting depends on John E. Friend II maintaining a continuous service relationship with Kazia Therapeutics through each applicable vesting date.
When do the Kazia Therapeutics (KZIA) CEO’s ADS options expire?
The ADS option reported in this filing expires on July 22, 2027. After that expiration date, any unexercised portion of the option would no longer be exercisable under the disclosed terms of the grant.
What change is being made in this Kazia Therapeutics (KZIA) Form 3/A amendment?
This amended Form 3 is being filed to correct the exercise price of the ADS option granted on July 22, 2024. It updates the earlier disclosure so the recorded option terms now reflect the accurate $18.85 exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
